UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake

Cancer research (Chicago, Ill.), 2018-01, Vol.78 (2), p.516-527

2018

Volltextzugriff (PDF)

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer

Oncotarget, 2017-12, Vol.8 (67), p.111026-111040

2017

Volltextzugriff (PDF)

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Cancer epidemiology, biomarkers & prevention, 2012-11, Vol.21 (11), p.1902-1912

2012

Volltextzugriff (PDF)

Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer

International journal of cancer, 2013-01, Vol.132 (2), p.472-484

2013

Volltextzugriff (PDF)

Clinical utility of CA-125 in the management of uterine carcinosarcoma

Journal of Gynecologic Oncology, 2018, 29(6), , pp.1-7

2018

Volltextzugriff (PDF)

Endometrial carcinoma: better prognosis for asymptomatic recurrences than for symptomatic cases found by routine follow-up

International journal of clinical oncology, 2010-08, Vol.15 (4), p.406-412

2010

Volltextzugriff (PDF)

Recurrent endometrial carcinoma: prognosis for patients with recurrence within 6 to 12 months is worse relative to those relapsing at 12 months or later

American journal of obstetrics and gynecology, 2011-06, Vol.204 (6), p.535.e1-535.e5

2011

Volltextzugriff (PDF)

Prediction, based on resection margins, of long-term outcome of cervical intraepithelial neoplasia 3 treated by Shimodaira-Taniguchi conization

Archives of gynecology and obstetrics, 2012-05, Vol.285 (5), p.1427-1432

2012

Volltextzugriff (PDF)

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP

International journal of oncology, 2017-04, Vol.50 (4), p.1064-1074

2017

Volltextzugriff (PDF)

Mid-second trimester measurement of fetal nasal bone length in the Japanese population

The journal of obstetrics and gynaecology research, 2006-08, Vol.32 (4), p.403-407

2006

Volltextzugriff (PDF)

Abstract 264: The cell cycle checkpoint kinase 1/2 inhibitor, LY2606368 with PARP inhibition results in synergistic cytotoxicity in high-grade serous ovarian cancer (HGSOC) at lower than physiologically administered concentrations

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.264-264

2016

Volltextzugriff (PDF)

Abstract 264: The cell cycle checkpoint kinase 12 inhibitor, LY2606368 with PARP inhibition results in synergistic cytotoxicity in high-grade serous ovarian cancer (HGSOC) at lower than physiologically administered concentrations

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.264-264

2016

Volltextzugriff (PDF)

Abstract 4410: LSR promotes ovarian cancer cell growth following the activation of β-oxidation and its antibody inhibits lipid catabolism

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4410-4410

2017

Volltextzugriff (PDF)

Abstract 5363: Navitoclax (Nav) and BMN 673 yield cytotoxicity with lower doses than used for single agents in high-grade serous ovarian cancer (HGSOC)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5363-5363

2015

Volltextzugriff (PDF)

Annexin A4‐conferred platinum resistance is mediated by the copper transporter ATP7A

International journal of cancer, 2014-04, Vol.134 (8), p.1796-1809

2014

Volltextzugriff (PDF)

Significance of venous thromboembolism in women with uterine carcinosarcoma

Gynecologic oncology, 2018-02, Vol.148 (2), p.267-274

2018

Volltextzugriff (PDF)

Abstract 4382: Anti-human LSR monoclonal antibody inhibits tumor growth of ovarian cancer directly

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4382-4382

2015

Volltextzugriff (PDF)

Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma

Gynecologic oncology, 2017-12, Vol.147 (3), p.565-571

2017

Volltextzugriff (PDF)

Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion

Gynecologic oncology, 2015-02, Vol.136 (2), p.198-204

2015

Volltextzugriff (PDF)

Abstract 4363: Silencing of JAM-A inhibits cell growth through cell cycle arrest in endometrial cancer

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4363-4363

2013

Volltextzugriff (PDF)

Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin

Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.829-835

2011

Volltextzugriff (PDF)

Abstract 4059: Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4059-4059

2013

Volltextzugriff (PDF)

Abstract 4057: Functional domain of Annexin A4: which domain is indispensable for chemoresistance to platinum drugs

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4057-4057

2013

Volltextzugriff (PDF)

Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A: Annexin A4-conferred platinum resistance

International journal of cancer, 2014-04, Vol.134 (8), p.1796-1809

2014

Volltextzugriff (PDF)

Clinical utility of CA-125 in the management of uterine carcinosarcoma

Journal of gynecologic oncology, 2018-11, p.1-7

2018

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Aktive Filter

ThemaUterine Neoplasms - Pathology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(34)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Humans
(15)
Female
(14)
Oncology
(14)
Middle Aged
(8)
Tumors
(8)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Obstetrics & Gynecology
(7)
Female Genital Diseases
(6)
Gynecology. Andrology. Obstetrics
(6)
Retrospective Studies
(6)
Adult
(5)
Endometrial Cancer
(5)
Aged
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Chemotherapy
(4)
Disease-Free Survival
(4)
Endometrial Neoplasms - Drug Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer

Clinical utility of CA-125 in the management of uterine carcinosarcoma

Endometrial carcinoma: better prognosis for asymptomatic recurrences than for symptomatic cases found by routine follow-up

Recurrent endometrial carcinoma: prognosis for patients with recurrence within 6 to 12 months is worse relative to those relapsing at 12 months or later

Prediction, based on resection margins, of long-term outcome of cervical intraepithelial neoplasia 3 treated by Shimodaira-Taniguchi conization

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP

Mid-second trimester measurement of fetal nasal bone length in the Japanese population

Abstract 264: The cell cycle checkpoint kinase 1/2 inhibitor, LY2606368 with PARP inhibition results in synergistic cytotoxicity in high-grade serous ovarian cancer (HGSOC) at lower than physiologically administered concentrations

Abstract 264: The cell cycle checkpoint kinase 12 inhibitor, LY2606368 with PARP inhibition results in synergistic cytotoxicity in high-grade serous ovarian cancer (HGSOC) at lower than physiologically administered concentrations

Abstract 4410: LSR promotes ovarian cancer cell growth following the activation of β-oxidation and its antibody inhibits lipid catabolism

Abstract 5363: Navitoclax (Nav) and BMN 673 yield cytotoxicity with lower doses than used for single agents in high-grade serous ovarian cancer (HGSOC)

Annexin A4‐conferred platinum resistance is mediated by the copper transporter ATP7A

Significance of venous thromboembolism in women with uterine carcinosarcoma

Abstract 4382: Anti-human LSR monoclonal antibody inhibits tumor growth of ovarian cancer directly

Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma

Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion

Abstract 4363: Silencing of JAM-A inhibits cell growth through cell cycle arrest in endometrial cancer

Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin

Abstract 4059: Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A

Abstract 4057: Functional domain of Annexin A4: which domain is indispensable for chemoresistance to platinum drugs

Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A: Annexin A4-conferred platinum resistance

Clinical utility of CA-125 in the management of uterine carcinosarcoma

Aktive Filter

Suchergebnisse filtern